DBV Technologies: Regulatory Noise Masks a Value Opportunity Ahead of a Pivotal BLA Filing
DBV Technologies (DBVT) is a clinical-stage immunotherapy play that recently squared up with the FDA around its BLA formatting and sequencing. The market has treated the story as binary and noisy, leaving the stock ~50% off its 52-week high despite positive Phase 3 VITESSE data and a planned BLA submission in Q3 2026. With roughly $190.6M in cash (…